Key result
Tyrosine kinase inhibitors, such as sunitinib and cediranib, and immunotherapy have redefined treatment paradigms and greatly improved outcomes for alveolar soft part sarcoma.
TKIs and immunotherapy have significantly improved outcomes for alveolar soft part sarcoma, redefining its treatment paradigm.
A recent randomized phase II study of sunitinib or cediranib in alveolar soft part sarcoma established benchmark activity for commonly used tyrosine kinase inhibitors (TKI). The impact of TKIs, as well as immunotherapy, has redefined treatment paradigms and greatly improved outcomes for this historically dismal sarcoma. See related article by Nguyen et al., p. 1200.
No takes yet. Share an insight, caveat, or question.
Wilky et al. (2023) studied this question. Tyrosine kinase inhibitors, such as sunitinib and cediranib, and immunotherapy have redefined treatment paradigms and greatly improved outcomes for alveolar soft part sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: